Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis.
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
PURPOSE: To compare the efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs), both used in combination with basal insulin, in patients with type 2 diabetes. DATA SOURCES AND STUDY SELECTION: Randomized controlled trials comparing the coadministration of short- or long-acting GLP-1 RAs and basal insulin with basal insulin ± placebo were identified (PubMed search). Of 974 identified publications, 14 clinical trials were included. Eight trials examined short-acting and six long-acting GLP-1 RAs. DATA EXTRACTION AND DATA SYNTHESIS: Differences in HbA1c, fasting plasma glucose, body weight, and adverse events were compared between studies using short- or long-acting GLP-1 RAs by random-effects meta-analysis. LIMITATIONS: There were relatively small numbers of available publications, some heterogeneity regarding protocols, and differences in the GLP-1 RA compound used. CONCLUSIONS: Long-acting GLP-1 RAs more effectively reduced HbA1c (∆ −6 mmol/mol [95% CI −10; −2], P = 0.007), fasting plasma glucose (∆ −0.7 mmol/L [−1.2; −0.3], P = 0.007), and body weight (∆ −1.4 kg [−2.2; −0.6], P = 0.002) and raised the proportion of patients achieving an HbA1c target <7.0% (<53 mmol/mol) (P = 0.03) more than the short-acting ones. Patients reporting symptomatic (P = 0.048) but not severe (P = 0.96) hypoglycemia were fewer with long- versus short-acting GLP-1 RAs added to insulin. A lower proportion of patients reported nausea (−52%, P < 0.0001) or vomiting (−36%, P = 0.0002) with long-acting GLP-1 RAs. Overall, GLP-1 RAs improved HbA1c, fasting plasma glucose, and body weight when added to basal insulin. However, long-acting GLP-1 RAs were significantly more effective for glycemic and body weight control and displayed better gastrointestinal tolerability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drugs such as Liraglutide and Semaglutide have demonstrated superior blood sugar control compared to placebo or alternative antihyperglycemic treatments. 75”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [75]
In the citing paper
“Although their effect on delaying gastric emptying is less pronounced than that of short-acting agents, they exhibit consistent and sustained efficacy in improving glycemic control and promoting weight reduction [21].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [21]
In the citing paper
“Nevertheless, in a network meta-analysis comparing short-acting and long-acting GLP-1RAs when used in conjunction with basal insulin, long-acting GLP-1RAs resulted in significantly greater reductions in glycated hemoglobin (HbA1c), fasting plasma glucose, and body weight compared to short-acting GLP-1RAs, with better gastrointestinal tolerability [15].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [15]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Research works printed but not linked: 1
- Buchholz, 2019, Clinical predictors of the need for further treatment escalation in patients with type 2 diabetes on basal insulin therapy - a retrospective observational study, 663
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Self-citationAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Self-citationSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials
Kapoor, I., Sarvepalli, S. M., D’Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.07.002 · Cited by 81
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Structural principles of insulin formulation and analog design: A century of innovation
Jarosinski, M. A., Dhayalan, B., Chen, Y., Chatterjee, D., Varas, N., & Weiss, M. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101325 · Cited by 58
Yeh, T.-L., Tsai, M.-C., Tsai, W.-H., Tu, Y.-K., & Chien, K.-L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0278685 · Cited by 50
Palanca, A., Ampudia-Blasco, F. J., Calderón, J. M., Sauri, I., Martinez-Hervás, S., Trillo, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01382-9 · Cited by 48
Krisanapan, P., Suppadungsuk, S., Sanpawithayakul, K., Thongprayoon, C., Pattharanitima, P., Tangpanithandee, S., Mao, M. A., Miao, J., & Cheungpasitporn, W. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae018 · Cited by 49
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Hankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Stefanski, A., & Garvey, W. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15269 · Cited by 44
Liang, Y., Liu, L.-Y., Jia, Y., Li, Y., Cai, J.-N., Shu, Y., Tan, J., Chen, P., Li, H., Cai, H., et al. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.861 · Cited by 42
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Ja’arah, D., Al Zoubi, M. S., Abdelhady, G., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 35
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Jarosinski, M. A., Chen, Y., Varas, N., Dhayalan, B., Chatterjee, D., & Weiss, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab849 · Cited by 26
Humos, B., Mahfoud, Z. R., Dargham, S. R., Suwaidi, J. M. S. A., Jneid, H. M., & Khalil, C. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.940035 · Cited by 24
Sharaiha, R. Z., Shukla, A. P., Sen, S., Chan, W. W., Broome, D. T., Anca, D., Abidi, W. M., Marya, N. B., Muniraj, T., Thosani, N. C., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.10.057 · Cited by 26
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 25
Harnessing the power of proteomics in precision diabetes medicine
Kurgan, N., Larsen, J. K., & Deshmukh, A. S. (2024) · Diabetologia · doi:10.1007/s00125-024-06097-5 · Cited by 24
Lisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
Retnakaran, R. R., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33867-9 · Cited by 22
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
Hoteit, B. H., Kotaich, J., Ftouni, H., Hazime, F., Safawi, A., Masri, R., & Marwani, M. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251383064 · Cited by 21
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Visolyi, G. Á., Domján, B. A., Svébis, M. M., Péterfi, A., Lovasz, B. D., Mészáros, S., Horváth, V. J., & Tabák, Á. G. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.03.002 · Cited by 18
Niu, C., Sun, K., Zhang, J., Elkhapery, A. M. R., Zhu, K., Malik, S., Xue, C., & Okolo, P. I., III (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003760 · Cited by 18
Jung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y., Park, J., Lee, W. J., & Jung, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870722 · Cited by 17
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
McLaughlin, S. A., Davila, N., Shields, C., Bineshfar, N., Banaee, T., & Williams, B. K. (2025) · Retina · doi:10.1097/iae.0000000000004616 · Cited by 14
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Tricò, D., & Solini, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.002 · Cited by 15
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 19
Le, T. T. B., Minh, L. H. N., Devi, P., Islam, N., & Sachmechi, I. (2024) · Cureus · doi:10.7759/cureus.51460 · Cited by 20
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Self-citationCeron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Individualized Glycemic Goals for Older Adults Are a Moving Target
Pilla, S. J., Yazdi, Z. S., & Taylor, S. I. (2022) · Diabetes Care · doi:10.2337/dci22-0004 · Cited by 11
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Fadini, G. P., Buzzetti, R., Pitocco, D., Tortato, E., Scatena, A., Lamacchia, O., Lastoria, G., Simoni, L., Consoli, A., & REX study group (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15486 · Cited by 12
Seno, Y., Ikeguchi, E., & Yabe, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00818-w · Cited by 10
Salmen, T., BOBIRCA, F. T., Bica, I.-C., Mihai, D. A., Pop, C. S., & Stoian, A. P. (2023) · Life · doi:10.3390/life13030839 · Cited by 11
Wu, Q., Zeng, Y., Liu, Y., Teng, F., Zhou, T., Guo, M., Jiang, Z., & Xu, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532587 · Cited by 10
Boye, K. S., Poon, J. L., Landó, L. F., Sapin, H., Huh, R., Wang, M., WILLIAMSON, S. E., & Patel, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01620-8 · Cited by 8
Cowart, K., Gonzalez, R. V. L., & Carris, N. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14579 · Cited by 7
Practicable Measurement and Identification of Overbasalization
Cowart, K., & Carris, N. W. (2021) · Clinical Diabetes · doi:10.2337/cd21-0096 · Cited by 8
Management of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Self-citationNovel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Kamrul-Hasan, A. B. M., Ganakumar, V., Nagendra, L., Dutta, D., Islam, M. R., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.103244 · Cited by 4
Salmen, T., Rizvi, A. A., Rizzo, M., Pietroșel, V.-A., Bica, I.-C., Diaconu, C.-T., Potcovaru, C.-G., Salmen, B.-M., Coman, O. A., Bobirca, A. V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092455 · Cited by 5
Retnakaran, R. R., Pu, J., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01781-z · Cited by 4
Morey‐Vargas, O. L., Gossmann, M., Ketz, J. M., & Abdelmalak, B. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24118 · Cited by 4
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Self-citationRegenerative Rehabilitation in Sarcopenia, Dynapenia, and Frailty
Baumann, C. W., Clark, B. C., Phillips, B. E., Szewczyk, N. J., & Consitt, L. A. (2022) · Physiology in health and disease · doi:10.1007/978-3-030-95884-8_5 · Cited by 4
Liu, X., Song, L., Zhang, Y., Li, H., Cui, C., & Liu, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1088670 · Cited by 5
Fériz, K., Rincón, A. R., Tovar, H., Restrepo-Erazo, K., Yepes, C. A., Brito, E. M., Gómez, N. B., Amézquita, Y. C. H., Iriarte-Durán, M. B., Jimenez, L., et al. (2025) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.12.3.907 · Cited by 3
Guo, M., Liu, Y., Zeng, Y., Chen, J., Zeng, C., Huang, L., Wang, J. H., Wu, Y., Wu, Q., Teng, F., et al. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70134 · Cited by 3
¿La insulina es un todoterreno?
Cuenca, A. M. C. (2021) · doi:10.52102/insulina/art-4 · Cited by 3
Cómo podemos optimizar la insulinización
Cosiales, P. B. (2021) · doi:10.52102/insulina/art-3 · Cited by 3
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Decrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?
Кушнарьова, Н. М., Zinych, О. В., Korpachev, V. V., Ковальчук, А., Prybyla, О. В., & Shyshkan-Shyshova, К. О. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.8.2021.246799 · Cited by 3
HbA1c reduction strategies: An overview of pharmacological interventions
Upadhye, K. S., Patidar, H., Bamnia, N., & Yadav, N. K. (2025) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_72_24 · Cited by 2
Hamann, A. (2020) · Die Diabetologie · doi:10.1007/s11428-020-00627-6 · Cited by 2
Wollenhaupt, D., Wolters, J., Aziz, M. A. E., & Nauck, M. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003296 · Cited by 1
Self-citationNarayanasamy, S., & Kalagara, H. K. P. (2024) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_609_24 · Cited by 2
Ruan, Z., Chen, X., Song, M., Jia, R., Luo, H., Ung, C. O. L., & Hu, H. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s483065 · Cited by 3
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Self-citationHamann, A. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00783-3 · Cited by 1
Kodama, S., Fujihara, K., Ishiguro, H., Matsubayashi, Y., Kitazawa, M., Iwanaga, M., Yamada, T., Kato, K., Nakagawa, Y., Tanaka, S., et al. (2023) · Journal of Investigative Medicine · doi:10.1177/10815589221149188 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Self-citationChung, S. M. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.69 · Cited by 1
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
¿Por qué no insulinizamos cuando es necesario?
Simarro, F. L. (2021) · doi:10.52102/insulina/art-1 · Cited by 1
Various and sundry recent publications
Bloomgarden, Z. T. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13122
Ito, H., Araki, R., Matsumoto, S., Izutsu, T., Kusano, E., Kondo, J., Inoue, H., Antoku, S., Yamasaki, T., Mori, T., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00508-3
Manov, A., Hatharasinghe, A. T., & Lopez, K. E. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.10.2.0215
GLP-1 receptor agonists: evolution and advancement in the treatment of type 2 diabetes mellitus
Candido, R. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.2.4
Cuándo y cómo iniciar la insulinización
Loiola, P. E. (2021) · doi:10.52102/insulina/art-2
Hu, Q.-J., & Zhu, J. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v20i5.26
Intensificación del tratamiento con insulina. Transición de pautas
Loiola, P. E., & Carbonell, A. M. P. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/algoritmo/art4 · Cited by 1
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/na230038 · Cited by 1
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Effects of GLP-1 receptor agonists on pituitary and adrenal hormones
Heinla, K. (2023) · DSpace repository (University of Tartu) · Cited by 4
Ραάτ, Α. Α., & Ραάτ, Α. Α. (2024) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.40414
Farmácia Avenida, Lamego e Serviços Farmacêuticos do Hospital Lusíadas Porto, Porto
Melo, B. M. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/qqhp-5e49
Yau, K. Y. T. (2025) · TSpace (University of Toronto)
Ganakumar, V., Fernandez, C. J., & Pappachan, J. M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.116477
Lipska, K. J., Zawack, K., Yan, L., Mutalik, P., Li, J., Gulanski, B., Ioannou, G. N., & Aslan, M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05216
Lin, C.-H., Hung, P., Chung, M., Wu, L.-Y., & Chung, C. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100645 · Cited by 2
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Glucagon-like-peptide-1 receptor agonists
Zhong, Q., Kruse, C., Glanz, T., Berges, M., & Eri, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.01015-0
Metadata
- Authors
- Huthmacher, J. A., Meier, J. J., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-08-11
- Volume
- 43
- Issue
- 9
- Pages
- 2303-2312
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3055103903
- Cited by
- 91
- References
- 44
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 17 · 2023: 17 · 2022: 18 · 2021: 19 · 2020: 3
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, basal insulin, glycemic control, HbA1c, fasting blood glucose, body weight, hypoglycemia, nausea and vomiting, gastrointestinal tolerance, drug safety, combination therapy, insulin intensification
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.